A rare disease is any disease that affects a small percentage of the population. In some parts of the world, an orphan disease is a rare disease whose rarity means there is a lack of a market large enough to gain support and resources for discovering treatments for it, except by the government granting economically advantageous conditions to creating and selling such treatments. Orphan drugs are ones so created or sold.
Most rare diseases are genetic and thus are present throughout the person's entire life, even if symptoms do not immediately appear. Many rare diseases appear early in life, and about 30% of children with rare diseases will die before reaching their fifth birthdays. With only four diagnosed patients in 27 years, ribose-5-phosphate isomerase deficiency is considered the rarest known genetic disease.
No single cut-off number has been agreed upon for which a disease is considered rare. A disease may be considered rare in one part of the world, or in a particular group of people, but be common in another.
There is no single, widely accepted definition for rare diseases. Some definitions rely solely on the number of people living with a disease, and other definitions include other factors, such as the existence of adequate treatments or the severity of the disease.
In the United States, the Rare Diseases Act of 2002 defines rare disease strictly according to prevalence, specifically "any disease or condition that affects fewer than 200,000 people in the United States", or about 1 in 1,500 people. This definition is essentially the same as that of the Orphan Drug Act of 1983, a federal law that was written to encourage research into rare diseases and possible cures.
In Japan, the legal definition of a rare disease is one that affects fewer than 50,000 patients in Japan, or about 1 in 2,500 people.
However, the European Commission on Public Health defines rare diseases as "life-threatening or chronically debilitating diseases which are of such low prevalence that special combined efforts are needed to address them". The term low prevalence is later defined as generally meaning fewer than 1 in 2,000 people. Diseases that are statistically rare, but not also life-threatening, chronically debilitating, or inadequately treated, are excluded from their definition.
|Country||Patient ratio as defined||Patient ratio standardised for comparison|
|Brazil||65 in 100,000||1 in 1,538|
|United States||<200,000 in population||1 in 1,659|
|Argentina||1 in 2,000||1 in 2,000|
|Australia||5 in 10,000||1 in 2,000|
|Chile||5 in 10,000||1 in 2,000|
|Colombia||1 in 2,000||1 in 2,000|
|European Union||5 in 10,000||1 in 2,000|
|Mexico||5 in 10,000||1 in 2,000|
|Norway||5 in 10,000||1 in 2,000|
|Panama||1 in 2,000||1 in 2,000|
|Singapore||1 in 2,000||1 in 2,000|
|Switzerland||5 in 10,000||1 in 2,000|
|United Kingdom||1 in 2,000||1 in 2,000|
|Japan||<50,000 in population||1 in 2,507|
|Russian Federation||10 in 100,000||1 in 10,000|
|Peru||1 in 100,000||1 in 100,000|
Relationship to orphan diseases
Because of definitions that include reference to treatment availability, a lack of resources, and severity of the disease, the term orphan disease is used as a synonym for rare disease. But in the United States and the European Union, "orphan diseases" have a distinct legal meaning.
The United States' Orphan Drug Act includes both rare diseases and any non-rare diseases "for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for such disease or condition will [be] recovered from sales in the United States of such drug" as orphan diseases.
Prevalence (number of people living with a disease at a given moment), rather than incidence (number of new diagnoses in a given year), is used to describe the impact of rare diseases. The Global Genes Project estimates some 300 million people worldwide are affected by a rare disease.
The European Organization for Rare Diseases (EURORDIS) estimates that as many as 5,000 to 7,000 distinct rare diseases exist, and as much as 6% to 8% of the population of the European Union is affected by one. Only about 400 rare diseases have therapies and about 80% have a genetic component according to Rare Genomics Institute.
Rare diseases can vary in prevalence between populations, so a disease that is rare in some populations may be common in others. This is especially true of genetic diseases and infectious diseases. An example is cystic fibrosis, a genetic disease: it is rare in most parts of Asia but relatively common in Europe and in populations of European descent. In smaller communities, the founder effect can result in a disease that is very rare worldwide being prevalent within the smaller community. Many infectious diseases are prevalent in a given geographic area but rare everywhere else. Other diseases, such as many rare forms of cancer, have no apparent pattern of distribution but are simply rare. The classification of other conditions depends in part on the population being studied: All forms of cancer in children are generally considered rare, because so few children develop cancer, but the same cancer in adults may be more common.
About 40 rare diseases have a far higher prevalence in Finland; these are known collectively as Finnish heritage disease. Similarly, there are rare genetic diseases among the Amish religious communities in the US and among ethnically Jewish people.
A rare disease is defined as one that affects fewer than 200,000 people across a broad range of possible disorders. Chronic genetic diseases are commonly classified as rare. Among numerous possibilities, rare diseases may result from bacterial or viral infections, allergies, chromosome disorders, degenerative and proliferative causes, affecting any body organ. Rare diseases may be chronic or incurable, although many short-term medical conditions are also rare diseases.
Public research and government policy
The NIH's Office of Rare Diseases Research (ORDR) was established by H.R. 4013/Public Law 107–280 in 2002. H.R. 4014, signed the same day, refers to the "Rare Diseases Orphan Product Development Act". Similar initiatives have been proposed in Europe. The ORDR also runs the Rare Diseases Clinical Research Network (RDCRN). The RDCRN provides support for clinical studies and facilitating collaboration, study enrollment and data sharing.
In 2013, the United Kingdom government published The UK Strategy for Rare Diseases which "aims to ensure no one gets left behind just because they have a rare disease", with 51 recommendations for care and treatment across the UK to be implemented by 2020. Health services in the four constituent countries agreed to adopt implementation plans by 2014, but by October 2016, the Health Service in England had not produced a plan and the all-party parliamentary group on Rare, Genetic and Undiagnosed Conditions produced a report Leaving No One Behind: Why England needs an implementation plan for the UK Strategy for Rare Diseases in February 2017. In March 2017 it was announced that NHS England would develop an implementation plan. In January 2018 NHS England published its Implementation Plan for the UK Strategy for Rare Diseases. In January 2021 the Department of Health and Social Care published the UK Rare Diseases Framework, a policy paper which included a commitment that the four nations would develop action plans, working with the rare disease community, and that "where possible, each nation will aim to publish the action plans in 2021". NHS England published England Rare Diseases Action Plan 2022 in February 2022.
Organisations around the world are exploring ways of involving people affected by rare diseases in helping shape future research, including using online methods to explore the perspectives of multiple stakeholders.
- National Organization for Rare Disorders (NORD)
- Undiagnosed Diseases Network (UDN)
- Orphanet (Online portal for rare diseases and orphan drugs)
- ICD coding for rare diseases
- List of rare disease organisations
- Orphanet Journal of Rare Diseases (academic journal)
- Rare Disease Day
- Idiopathic disease
- Mystery Diagnosis
- Health care rationing
- "Rare Diseases". Siope.Eu. 9 June 2009. Archived from the original on 3 December 2012. Retrieved 24 September 2012.
- Kaur, Parneet; Wamelink, Mirjam M. C.; van der Knaap, Marjo S.; Girisha, Katta Mohan; Shukla, Anju (1 August 2019). "Confirmation of a Rare Genetic Leukoencephalopathy due to a Novel Bi-allelic Variant in RPIA". European Journal of Medical Genetics. 62 (8): 103708. doi:10.1016/j.ejmg.2019.103708. ISSN 1769-7212.
- "RARE List". Global Genes. 15 April 2016. Retrieved 15 April 2016.
- "Rare Disease Act of 2002". United States Congress. Retrieved 21 January 2022.
- "Rare diseases: what are we talking about?". Rare diseases centre - Venetian Region - Italy. Retrieved 21 January 2022.
- "Useful Information on Rare Diseases from an EU Perspective" (PDF). European Commission. Retrieved 19 May 2009.
- Baldovino S, Moliner AM, Taruscio D, Daina E, Roccatello D (June 2016). "Rare Diseases in Europe: from a Wide to a Local Perspective" (PDF). The Israel Medical Association Journal (Review). 18 (6): 359–63. PMID 27468531.
- "KEI Briefing Note 2020:4 Selected Government Definitions of Orphan or Rare Diseases". Knowledge Ecology International. Retrieved 12 September 2021.
- "The UK Rare Diseases Framework". GOV.UK. 9 January 2021. Retrieved 12 September 2021.
- Orphan Drug Act §526(a)(2)
- "Rare Diseases: Understanding This Public Health Priority" (PDF). European Organisation for Rare Diseases (EURORDIS). November 2005. Retrieved 16 May 2009.
- Sanfilippo, Ana; Lin, Jimmy (2014). Rare Diseases, Diagnosis, Therapies, and Hope. St. Louis, MO: Rare Genomics Institute. p. 6.
- "02/2009: Rare Cancers on Rare Disease Day". Ecpc-online.org. 28 February 2009. Archived from the original on 26 July 2011. Retrieved 24 September 2012.
- "Genetic and Rare Diseases Information Center". National Center for Advancing Translational Sciences, US National Institutes of Health. 2019. Retrieved 12 October 2019.
- Aymé S, Schmidtke J (December 2007). "Networking for rare diseases: a necessity for Europe". Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 50 (12): 1477–83. doi:10.1007/s00103-007-0381-9. PMID 18026888. S2CID 36072660.
- "President Signs Bills into Law".
- "NORD - National Organization for Rare Disorders, Inc". Archived from the original on 18 June 2008.
- The UK Strategy for Rare Diseases (PDF). Department of Health. 2013. Retrieved 26 October 2017.
- All Party Parliamentary Group on Rare, Genetic and Undiagnosed Conditions (February 2017). Leaving No One Behind: Why England needs an implementation plan for the UK Strategy for Rare Diseases (PDF). Rare Disease UK. Retrieved 29 January 2018.
- "The Westminster All Party Parliamentary Group on Rare, Genetic and Undiagnosed Conditions". Genetic Alliance UK. Retrieved 26 October 2017.
- Implementation Plan for the UK Strategy for Rare Diseases (PDF). NHS England. 29 January 2018. Retrieved 29 January 2018.
- "The UK Rare Diseases Framework". GOV.UK. Department of Health and Social Care. 9 January 2021. Retrieved 12 January 2021.
- "England Rare Diseases Action Plan 2022". GOV.UK. Department of Health & Social Care. Retrieved 22 March 2022.
- Nunn JS, Gwynne K, Gray S, Lacaze P (March 2021). "Involving people affected by a rare condition in shaping future genomic research". Research Involvement and Engagement. 7 (1): 14. doi:10.1186/s40900-021-00256-3. PMC 7958104. PMID 33722276.
- "February 29th Is The First Rare Disease Day". Medical News Today. 28 February 2008. Retrieved 14 February 2009.
- "Join Us In Observing Rare Disease Day On Feb. 28, 2009!". National Organization for Rare Disorders. Archived from the original on 18 December 2008.
- "Millions Around World to Observe Rare Disease Day". PR Newswire. 13 February 2009. Retrieved 14 February 2009.[permanent dead link]
- "Rare Diseases Day: Experts call for more research for patients' welfare". The Indian Express. 28 February 2021. Retrieved 12 September 2021.